Eagle Pharmaceuticals (NASDAQ:EGRX) Earns Hold Rating from Analysts at StockNews.com

Stock analysts at StockNews.com initiated coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRX) in a research note issued on Thursday. The firm set a “hold” rating on the specialty pharmaceutical company’s stock.

Eagle Pharmaceuticals Price Performance

Eagle Pharmaceuticals stock opened at $1.99 on Thursday. Eagle Pharmaceuticals has a 12 month low of $1.50 and a 12 month high of $2.00. The business’s fifty day simple moving average is $1.50 and its two-hundred day simple moving average is $1.03.

Institutional Trading of Eagle Pharmaceuticals

A hedge fund recently bought a new stake in Eagle Pharmaceuticals stock. Jane Street Group LLC acquired a new stake in Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 25,837 shares of the specialty pharmaceutical company’s stock, valued at approximately $96,000. Jane Street Group LLC owned approximately 0.20% of Eagle Pharmaceuticals at the end of the most recent quarter. 85.36% of the stock is owned by institutional investors.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma.